Efficacy of a Spatial Repellent for Control of *Aedes*-Borne Virus Transmission: A Cluster Randomized Trial in Iquitos, Peru

Amy C. Morrison, Ph.D.[1,2+], Robert C. Reiner Jr., Ph.D.[3+], William H. Elson, M.B.B.S.[4], Helvio Astete, M.S.[2], Carolina Guevara, M.S.[2], Clara del Aguila, B.S.[5], Isabel Bazan, M.D.[2], Crystyan Siles, M.D.[2], Patricia Barrera, M.S.[2], Anna B. Kawiecki, M.S.[1], Christopher M. Barker, Ph.D.[1], Gissella M. Vasquez, Ph.D.[6], Karin Escobedo-Vargas, B.S.[6], Carmen Flores-Mendoza, Ph.D.[6], Alfredo A. Huaman, B.S.[2], Mariana Leguia, Ph.D.[7], Maria E. Silva, Ph.D.,[2] Sarah A. Jenkins, Ph.D.[2], Wesley R. Campbell, M.D.[2], Eugenio J. Abente, Ph.D.[2], Robert D. Hontz, Ph.D.[2], Valerie A. Paz-Soldan, Ph.D.[8], John P. Grieco, Ph.D.[9], Neil F. Lobo, Ph.D.[9+], Thomas W. Scott, Ph.D.[4+], and Nicole L. Achee, Ph.D.[9+*]

[1] Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, California, USA

[2] Department of Virology and Emerging Infectious Diseases, U.S. Naval Medical Research Unit No. 6, Lima, Peru

[3] Department of Health Metrics Sciences, University of Washington, Seattle, Washington, USA

[4] Department of Entomology and Nematology, University of California, Davis, California, USA

[5] Dirección General de Saneamiento Ambiental (DIGESA), Calle Alzamora 410, Iquitos, Peru

[6] Department of Entomology, U.S. Naval Medical Research Unit No. 6, Lima, Peru

[7] Genomics Laboratory, Pontificia Universidad Católica del Perú, Av. Universitaria 1801, San Miguel, Lima, Peru

[8] Department of Global Community Health and Behavioral Sciences, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA

[9] Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, 239 Galvin Life Sciences Center. Notre Dame, Indiana, USA

[+]Indicates equal seniority

*Corresponding author:
Nicole L. Achee, PhD
Research Professor
Eck Institute for Global Health
Department of Biological Sciences
239 Galvin Life Science Center
Notre Dame, Indiana 46556
Ph: 574.631.1561
Email: nachee@nd.edu

ABSTRACT

Background: Over half the world's population is at risk for viruses transmitted by *Aedes* mosquitoes, such as, dengue and Zika. The primary vector, *Aedes aegypti*, thrives in urban environments. Despite decades of effort, cases and the geographic range of *Aedes*-borne viruses (ABV) continue to expand. To date, there are no rigorously proven vector control interventions that prevent ABV diseases. Spatial repellents, a new option, are designed to decrease human exposure to ABV by releasing active ingredients into the air that disrupt mosquito-human contact.

Methods: A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru to quantify the impact of a transfluthrin-based spatial repellent on ABV infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683 participants (secondary endpoint). Bi-monthly adult mosquito collections were conducted to compare *Ae. aegypti* abundance, blood-fed capture rate and parity status through mixed effect difference-in-difference analyses.

Results: The spatial repellent significantly reduced ABV infection by 34.1% (95% CI 6.9%, ∞); p = 0.0236, z=1.98). *Aedes aegypti* abundance and blood-fed capture rates were significantly reduced by 28.6% (95% CI 24.1%, ∞); z=-9.11) and 12.4% (95% CI 4.2%, ∞); z=-2.43), respectively.

Conclusions: Our trial provides the first conclusive evidence of significant protective efficacy by any chemical vector control intervention, in this case a spatial repellent, to reduce the risk of ABV transmission. Results support vector control as a beneficial component to ABV disease prevention.

Trial registration number: NCT03553277 (clinicaltrials.gov)

Introduction

Aedes-borne viral diseases (ABVD) [e.g., dengue (DENV), chikungunya (CHIKV), Zika (ZIKV), and yellow fever (YF)] are devastating, expanding global public health threats that disproportionally affect low- and middle-income countries. Currently, the primary means for ABVD prevention is controlling the primary mosquito vector, *Aedes aegypti*. Existing vector control interventions, however, have failed to prevent ABV transmission and epidemics. Dengue alone, one of the most rapidly increasing vector-borne infectious diseases,[1,2] with 4 billion people at risk of infection annually,[3] results in 400 million infections each year.[2]

There is an urgent need to develop evidence-based guidance for the use of new and existing ABV vector control tools. The evidence-base for vector control against ABVs is weak, despite considerable government investments in WHO-recommended control of larval habitats (larviciding, container removal) and ultra-low volume (ULV) insecticide spraying.[4–8] These strategies continue to be implemented despite the lack of rigorously generated data from controlled clinical trials demonstrating they reduce ABV infection and disease.[9] The only ABV intervention with a proven epidemiological impact in a cluster randomized control trial (cRCT) assessed community mobilization to reduce mosquito larval habitats.[10] A recent test-negative trial with *Wolbachia*-infected mosquitoes reported a significant reduction of dengue illness in Indonesia.[11]

Spatial repellents (SR) are devices that contain volatile active ingredients that disperse in air. The active ingredients can repel mosquitoes from entering a treated

space, inhibit attraction to human host cues or disrupt mosquito biting and blood feeding behavior, and, thus, interfere with mosquito-human contact.[12–14] Any of these outcomes reduce the probability of pathogen transmission. Pyrethroid-based spatial repellents have shown efficacy in reducing malaria infections in China[15] and Indonesia.[16] There have, however, been no clinical trials evaluating the protective efficacy of spatial repellents against ABV infection or disease.

To generate evidence for public health consideration we conducted a parallel, cluster-randomized controlled trial (cRCT) to quantify the epidemiological impact of a transfluthrin-based spatial repellent against ABV transmission in Iquitos, Peru.

Methods

The trial is registered at clinicaltrials.gov (NCT03553277).

ETHICAL STATEMENT

Our study protocol (#NAMRU6.2014.0021, **Supplementary Information (SI)**) was approved by the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional Review Board (IRB), which includes Peruvian representation and complies with US Federal and Peruvian regulations governing the protections of human subjects, and the Regional Health Authority (DIRESA), the local branch of the Peruvian Ministry of Health. IRB authorization agreements were established between the NAMRU-6, the University of Notre Dame (Sponsor), the University of California at Davis, and the University of Washington.

128

129 **TRIAL DESIGN**

130 Detailed study methods are provided in the SI.

131

132 Our trial was conducted from June 2015 through March 2019 in the Iquitos and
133 Punchana Districts of Iquitos, Peru **(Figure 1, SI Section 1.1)**. Clusters were
134 selected in January 2015. Enrollment began June 2015. Participation included: 1) a
135 house census, 2) disease surveillance, 3) annual blood draws, 4) bi-monthly
136 entomological surveys, and 5) intervention application in the house. Epidemiological
137 monitoring and entomological surveillance lasted from February 2016 through March
138 2019 **(Figure 2).**

139

140 Our main objective was to demonstrate and quantify the protective efficacy (PE) of a
141 SR in reducing ABV infection incidence in a human cohort. Qualifying participants
142 were individuals in a participating house who were seronegative or had a monotypic
143 DENV antibody response when they entered the trial. Assuming the probability of
144 seroconversion for seronegative or monotypic individuals was 10% with a coefficient
145 of variation of 0.25, and an alpha of 5%, we estimated we would need 26 clusters (13
146 per arm) with approximately 60 qualifying individuals to achieve a power of 80% to
147 detect a reduction in the odds of 30%.

148

149 The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-
150 specific neutralizing antibodies, in blood from children $\geq$2 years to $\leq$18 years. To

151 increase the pool of baseline seronegative participants, we expanded screening to
152 ≥18 years. Secondary endpoints were clinically apparent laboratory confirmed ABV
153 disease and indoor female *Ae.* aegypti: 1) abundance, 2) blood-fed status (proxy for
154 human-biting rates), and 3) parity status (proxy for age-structure). Participants
155 followed for seroconversion were the 'longitudinal cohort' and those followed for
156 disease were the 'febrile surveillance cohort'.
157

158 **RANDOMIZATION AND INTERVENTION**

159 A total of 26 clusters (13 per arm) each with approximately 140 households (60
160 qualifying participants) were randomly allocated in August 2016 to receive SR or
161 placebo intervention by the external statistician serving on the Data Safety Monitoring
162 Board (DSMB) using a random number generator (https://www.random.org) (**SI**
163 **Section 1.2.1**). Investigators, research staff, and study participants were blinded to
164 cluster allocation. Our intervention was a transfluthrin passive emanator designed
165 and produced by SC Johnson (Racine, WI), replaced at 2-week intervals, as
166 described previously (**Figure S1, SI Section 1.3.2**).[16] Spatial repellent and placebo
167 intervention had identical packaging and were deployed in houses by study personnel
168 using a blinded coding scheme. The placement of the intervention followed
169 manufacturer specifications for indoor use conditions.
170

171 **SEROCONVERSION AND DISEASE SURVEILLANCE**

172 Recruitment for the longitudinal cohort focused on children because they were likely
173 to be antibody test-negative or monotypic at baseline, which would facilitate

174 interpretation of laboratory assays, and less mobile than adults[17], thus spending more
175 time in their houses or their assigned cluster. Baseline blood samples were obtained
176 within 2 weeks before or after initial intervention deployment. As new families moved
177 into the study area, they were recruited to participate, resulting in longitudinal
178 participant enrollment throughout the interval between Baseline (B), First (F), and
179 Second/Final (S) longitudinal blood draws (**Figure 3**). Samples were tested by
180 microneutralization enzyme immunoassay (MNT) for seroconversion to each DENV
181 serotype and ZIKV (**SI Sections 1.3.3.1 and 1.3.4.1**). Only participants that provided
182 at least 2 blood samples were included in final analyses.
183
184 The febrile surveillance cohort was recruited by nurse technicians during door-to-door
185 wellness starting with the first week of intervention deployment. Suspected cases
186 exhibited axillary temperature of ≥ 37.5°C or, for suspected ZIKV infection, absence
187 of fever but presence of rash, arthralgia, arthritis, or non-purulent conjunctivitis for ≤
188 five days. Participants meeting these criteria provided acute and convalescent (14–21
189 days later) serum samples and were monitored clinically daily. Acute serum samples
190 were tested for viral RNA by PCR (DENV and ZIKV; **SI Sections 1.3.3.2-1.3.3.4**) and
191 by ELISA for DENV IgM (**SI Sections 1.3.3.5,1.3.4.2**).
192
193 **ENTOMOLOGICAL ENDPOINTS**
194 Indoor Prokopack aspirations[18] were conducted in all consented homes at time of first
195 intervention deployment and subsequent intervention replacement; i.e., two-week
196 intervals. Adult mosquitoes were transported to the NAMRU-6 Iquitos laboratory,

197 sedated at 4°C, identified to species and sex, counted by date and house. Up to 30
198 female *Ae. aegypti* per household per collection were examined for blood meal status
199 and scored as unfed, blood-fed (fully engorged, half-engorged, or trace amounts), or
200 gravid[19]. Standard insecticide resistance assays were used to assess vector
201 susceptibility to transfluthrin one-year into the trial (**SI Section 1.3.5.2**).
202

203 **SAFETY MONITORING**

204 Adverse events (AEs) and serious adverse events (SAEs) were actively collected
205 throughout the trial during surveillance follow-up and entomological surveys **(SI**
206 **Section 1.3.6)**. Reported AEs were investigated by study staff and appropriate care
207 was recommended by a study physician within 24 hours. Safety reporting to the
208 NAMRU-6 IRB was managed by UC Davis in accordance with the approved protocol.
209 Quarterly reports summarizing reported AEs and SAEs were reviewed by the DSMB
210 for trial safety assessment.
211

212 **STATISTICAL ANALYSIS**

213 Details of our analytical approach are provided in the statistical analysis plan (SAP)
214 and **SI Section 1.5**. All analyses were conducted by RCR using R 3.6.1 (R Core
215 Team)[20] and the lme4[21] and survival[22] packages. No correction for multiple testing
216 was performed for secondary endpoint analyses and, as such, in accordance with
217 CONSORT guidelines, we do not present p-values.
218

The primary analysis was an intent-to-treat (ITT) assessment of ABV seroconversion for all qualifying participants per treatment assignment who were ≥2 years to ≤18 years of age. Due to the rolling nature of enrollment, we used a survival analysis with a proportional hazards model and exponential distribution assumption for the baseline hazard (i.e., constant baseline hazard through time) and a frailty component to account for correlation within clusters. If $h(t_{ij}\,|x_{ij})$ is the hazard rate of the jth individual in the ith cluster with covariate values x_{ij} then this individual's hazard rate of an arbovirus infection can be written as:

$$h(t_{ij}\,|\,x_{ij}\,) = h_0\,(t_{ij}\,) \cdot \exp(\boldsymbol{\beta}^T \boldsymbol{x}_{ij} + W_i)$$

where $W_i \sim N(0, \sigma_c^2)$ is the random effect of the ith cluster. Covariates included age, sex, and treatment status (SR or placebo). PE was estimated as $PE = \left(1 - \exp(\hat{\beta})\right) \times 100\%$, where $\hat{\beta}$ is the estimated regression coefficient for the intervention group and $\exp(\hat{\beta})$ is the estimated hazard ratio (HR) between SR and placebo. The null hypothesis of PE = 0% is equivalent to $\beta = 0$, which is tested by Wald's test $z = \beta/s$, where s is the estimated standard error of $\hat{\beta}$, at the 1-sided significance level of 5%.

A Poisson generalized linear regression was used to assess intervention impact on clinical disease, with an offset for the number of participant-days each participant spent in each cluster. No covariates were used and due to the small sample size, no random effects were incorporated.

242

243 Indoor adult female *Ae. aegypti* abundance, blood-fed rates, and parity were tested
244 through a difference-in-difference Poisson generalized linear mixed models.
245 Collections conducted in 2016 were defined as 'baseline' and collections conducted
246 in 2017 and 2018 were estimated as 'post-baseline'. Each analysis accounted for
247 month of year and year as fixed effects and contained a random effect by cluster.
248 Model formulation details are in **SI Sections 1.5.4-1.5.6**.

249

250 The primary analysis conducted differs from that in the original SAP (SI SAP).
251 Procedures called for yearly blood draws from children. To increase the number of
252 qualifying participants, an expansion of the age range to all ages ≥2yrs. The rolling
253 enrollment resulted in substantial variation in time intervals between blood draws.
254 Simple logistic regression, therefore, was inadequate. The decision to alter the
255 primary analysis was discussed and agreed upon by the study statistician and the
256 external DSMB statistician before outputs were unblinded to the DSMB statistician.

257

258 Results

259 STUDY POPULATION

260 A total of 2,215 persons were enrolled in the longitudinal cohort. Of these, 1,578
261 qualifying participants were included in the ITT analysis for seroconversion (**Figure 3)**
262 representing a total of 196 ABV infections from 754 (1,090 paired samples) qualifying
263 participants in the SR arm and 294 ABV infections from 824 (1,237 paired samples)

264 qualifying participants in the placebo arm. Baseline covariates were balanced at both
265 the cluster and individual level (**Table 1**).
266
267 A total of 16,707 participants were followed for clinical disease of which 16,683 were
268 included in the ITT analysis **(Figure S2)**. Baseline covariates for analysis of the
269 secondary endpoint were balanced at both the cluster and individual level (**Table S5).**
270
271 **SPATIAL REPELLENT EFFICACY**
272 The estimated PE of SR intervention was 34.1% (1-sided 95% CI lower limit, 6.9%;
273 **(Table 2)**. Reduction in the arbovirus infection hazard rate was significant at the 5%
274 significance level (Test statistic: z=1.98, 1-sided p-value = 0.02). The originally
275 proposed analysis indicates a consistent result to those presented here; i.e., PE >
276 30% and statistical significance at the 5% level.
277
278 There were 96 disease cases detected, 51 in the SR arm and 45 in the placebo arm,
279 from 10,793,792 participant days which appeared balanced between SR and placebo
280 clusters (**Table S5).**
281
282 The estimated reduction adult female *Ae. aegypti* abundance in clusters receiving SR
283 intervention was 28.6% (1-sided 95% CI lower limit: 24.1%, test statistic: $z = -9.11$).
284 Baseline abundance was balanced between treatment arms (**Table S6**) with post-
285 baseline quantities estimated based on 47,518 and 43,417 household collections in
286 SR and placebo arms, respectively. Baseline abundance averaged 0.277 (standard

287 deviation [SD] 0.153) and 0.279 (SD 0.122) per house collection in SR and placebo
288 arms, respectively, whereas post-baseline abundance averaged 0.276 (SD 0.091)
289 and 0.391 (SD 0.142) in the SR and placebo arms, respectively **(Table S8)**. There
290 was a strong indication of seasonality, with z-scores comparing each month to the
291 reference month of January being at least 6 away from 0 **(Table S9)**.
292
293 The estimated reduction in the rate of blood-fed *Ae. aegypti* collected inside houses
294 was 12.4% (1-sided 95% CI lower limit: 4.2%, test statistic: $z = -2.430$) **(Table S8)**.
295 Baseline abundance of engorged *Ae. aegypti* was balanced treatment arms **(Table**
296 **S6)** with post-baseline quantities estimated based on 9,257 and 11,496 mosquitoes
297 assessed for blood-fed status in SR and placebo arms, respectively. Baseline
298 abundance of blood-fed mosquitoes averaged 0.593 (standard deviation 0.440) and
299 0.536 (standard deviation 0.451) per collection in SR and placebo arms, respectively,
300 and post-baseline rates averaged 0.606 (SD 0.460) and 0.634 (SD 0.447) in SR and
301 placebo arms, respectively**.** There was no strong indication of seasonality **(Table**
302 **S10)**.
303
304 There was no observed intervention effect on the parity rate of *Ae. aegypti* females
305 (**Table S8**).
306
307 **ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE).**
308 There were 29 AEs reported during the trial (**SI Section 2.8**). Of these, 3 were
309 associated with blood draw (vasovagal response, 2 from SR and 1 from placebo

310 clusters) and 26 were consistent with transfluthrin (pyrethroid) exposure (22 from SR
311 and 4 from placebo clusters). Of the latter, the 26 affected individuals came from 18
312 households, often reporting different combinations of the following symptoms: allergic
313 response with itching and skin irritations (n=19; 15 from SR, 4 from placebo clusters),
314 dry mouth/bad taste (n=5, from SR clusters only), breathing issues (n=7, from SR
315 clusters only) including exacerbation of chronic bronchitis or asthma (n=2), and
316 headaches (n=4, from SR clusters only). No reported SAEs (deaths) were deemed
317 associated with the spatial repellent intervention.
318

319 ## Discussion

320 Arbovirus disease threats come from multiple viruses, which have expanding regions
321 of transmission and increasingly frequent epidemics. There is, therefore, a growing
322 unmet need for effective ABV disease prevention.[9] Our cRCT provides the first
323 conclusive evidence of significant PE against human ABV infection by any chemical-
324 based vector control intervention, in this case a spatial repellent.
325

326 PE was detected despite assumed dilution and contamination effects due to
327 participant movement in and out of study clusters. Our outcome was demonstrated in
328 an operational context, reflecting complex interactions among ongoing Ministry of
329 Health interventions across the study area, imperfect coverage at the household-level
330 (rooms closed to intervention, homeowner removal and/or loss of intervention),
331 <100% household participation within clusters, and suggestion of pyrethroid
332 resistance in the local *Ae. aegypti* population.[23(**SI section 2.7**)] Reduced risk of ABV

333 infection was associated with a significant reduction in indoor female *Ae. aegypti*
334 abundance and blood feeding. Although entomological outcomes were modest, these
335 effects are consistent with the expected mode of action of SRs; i.e., deterrence from
336 house entry and/or interfering with human-biting.[12,24] Entomological data will help
337 guide indicators for next-generation product development.
338
339 Our results support SRs as a flexible class of vector control products with positive
340 public health impact not limited to ABV diseases. Transfluthrin-[15] and metofluthrin-
341 based[16,25] mosquito coils have been shown to reduce malaria and the same spatial
342 repellent device used in our Iquitos trial reduced malaria infections in an Indonesia
343 cRCT.[15] Together, these results highlight the potential for SRs to reduce a variety of
344 vector-borne diseases, augment existing public health efforts and be an effective
345 component of vector control intervention strategies. To help guide implementation
346 and programmatic scale-up, additional assessments, which have already begun, [26–29]
347 are needed.
348
349 Our Peru cRCT is one of two trials recommended by the WHO for assessing public
350 health value and developing global health policy for the SR intervention class.[30] Our
351 study was powered to detect a 30% reduction in ABV infection risk. During the trial
352 period, dengue prevalence was lower than previous years and a Zika epidemic
353 occurred in 2016.[31] This uncertainty is typical of ABV transmission, making powering
354 of cRCTs challenging and helps explain why, until now, ABV cRCTs with
355 epidemiological outcomes have been rare.[32] We used seroconversion as our primary

356 endpoint of PE to address this challenge. In our setting, powering a trial based on
357 clinically apparent ABV disease would not be logistically feasible.
358
359 Fully integrating vector control into ABV disease prevention programs will require
360 quantitative guidance based on the impact contribution from each intervention
361 component. Ministries of Health, local to national governments, and non-
362 governmental organizations can use our trial results as an evidence-base for
363 informed application of SRs. Considering the growing ABV public health threat,
364 difficulties of developing vaccines against multiple viruses and past, poorly informed
365 vector control failures,[9] enhanced ABV disease prevention will benefit greatly from
366 interventions with proven public health value.
367
368

Acknowledgements

We extend sincere appreciation to DSMB members: Dennis Shanks, Chris Drakeley, and Neal Alexander for assurances on data integrity and safety assessments. We thank the WHO Vector Control Advisory Group (VCAG) for their comments during project assessments. We are grateful for the efforts of Marianne Kent, Program Coordinator at the University of Notre Dame, for her administrative, and logistical support of the program, as well as, Brett Fox of the University of Notre Dame Center for Research Computing for assisting with central database development for data verification. We thank Kristina Davis and Matthew Sisk of the University of Notre Dame Center for Research Computing and Hesburgh Libraries, respectively, for their assistance in graphic development. We acknowledge Audrey Lenhart of the Centers for Disease Control and Prevention (CDC) in Atlanta, GA USA and J. Kevin Baird of the Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Nuffield Department of Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom for their role on the Scientific Advisory Committee.

We express our gratitude to the Bill and Melinda Gates Foundation for their long-term generosity and support of spatial repellent product evaluation and development, especially Kate Aultman, Dan Strickman, and Alan Magill. We are deeply grateful to SC Johnson for providing integral industry and product expertise including the independent funding of the development, manufacturing, delivery, and shipment of the intervention (SR and placebo) used in the study. SC Johnson provided expertise

392 in ensuring intervention quality, storage, application and disposal assurances
393 throughout the trial.
394
395 We thank the residents of Iquitos for their support and participation in this study and
396 willingness to allow this study to be conducted in their community. We greatly
397 appreciate support of the Loreto Regional Health Department including Drs. Hugo
398 Rodriguez-Ferruci, Christian Carey, Carlos Alvarez, and Lic. Wilma Casanova Rojas,
399 who facilitated our work in Iquitos. We thank the NAMRU-6 Virology and Emerging
400 Infections Department (VEID) leadership who provided institutional support, IRB
401 guidance, and support supervising field staff. We appreciate the careful commentary
402 and advice provided by the NAMRU-6 IRB and Research Administration Program for
403 the duration of this study. We thank the NAMRU-6 VEID field who provided daily
404 support through the duration of the project and without whom the recruitment of acute
405 dengue cases would not have been possible. In particular, we thank Cecilia
406 Gonzales, Gloria Talledo, and Gabriela Vasquez de la Torre for their administrative
407 support of the project.
408

409 **Author contributions**

410 Data were gathered by the field team in Iquitos (ACM, WHE, HA, IB, CS, and ABK);
411 laboratory testing by CG, PB, and AH; insecticide resistance testing by GMV, KEV,
412 and CFM; and human use issues were managed by ACM, SAJ, and WRC. ML
413 developed a Zika virus PCR assay used in the study. CDA provided Ministry of
414 Health entomological information and coordinated activities with Iquitos field teams.
415 The NAMRU-6 supervisory team in Lima included MS, SAJ, WRC, EJA, and RHD.

416 CM provided data management and ZIKV MNT laboratory testing. Statistical analysis
417 was conducted by RCR. The first draft of the manuscript was written by ACM, RCR,
418 TWS, and NLA, with revision following comments from all the authors.
419

420 **Copyright statement**

421 SAJ, WRC, EJA and RDH are military service members and ACM, HA, CG, IB, CS,
422 GMV, KE, CF, AAH, and MES are employees of the U.S. Government. This work was
423 prepared as part of their official duties. Title 17 U.S.C. §105 provides that "Copyright
424 protection under this Title is not available for any work of the United States
425 Government". Title 17 U.S.C. §101 defines a U.S. Government work as a work
426 prepared by a military service member or employee of the U.S. Government as part
427 of that person's official duties.
428

429 **Disclaimer**

430 The views expressed in this article are those of the author and do not necessarily
431 reflect the official policy or position of the Department of the Navy, Department of
432 Defense, nor the U.S. Government.
433

434 **Financial disclosure statement**

435 This study was funded by the Bill and Melinda Gates Foundation (BMGF) to the
436 University of Notre Dame (Grant# OPP1081737). Further support was provided by
437 the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research
438 Program (MIDRP, S0520_15_LI and S0572_17_LI), and the U.S. National Institute of
439 Allergy and Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC

Johnson used internal company financial resources for the development, manufacturing, delivery, and shipment of the intervention (SR and placebo) used in the study.

Competing interests

The authors have declared that no competing interests exist.

References

1. Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 2015;386(10009):2145–91.

2. Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16(6):712–23.

3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496(7446):504–7.

4. Parks W, Lloyd L. Planning social mobilizaiton and communication for dengue fever prevention and control. Geneva: WHO; 2004.

460 5. Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space
461 spraying with insecticide on dengue transmission; systematic review. Trop Med
462 Int Health 2010;15(5):619–31.

463 6. Horstick O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control
464 services: how do they work? A systematic literature review and country case
465 studies. Trans R Soc Trop Med Hyg 2010;104(6):379–86.

466 7. Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in
467 Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl
468 Trop Dis 2016;10(3):e0004551.

469 8. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges
470 and proposing solutions for control of the virus vector Aedes aegypti. PLoS Med
471 2008;5(3):e68.

472 9. Achee NL, Gould F, Perkins TA, et al. A critical assessment of vector control for
473 dengue prevention. PLoS Negl Trop Dis 2015;9(5):e0003655.

474 10. Andersson N, Nava-Aguilera E, Arostegui J, et al. Evidence based community
475 mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the
476 Green Way): cluster randomized controlled trial. BMJ 2015;351:h3267.

477 11. RCT-WMP%20Indo-factsheet.pdf. Available from:
478 https://www.worldmosquitoprogram.org/sites/default/files/2020-08/RCT-
479 WMP%20Indo-factsheet.pdf

480 12. Achee NL, Bangs MJ, Farlow R, et al. Spatial repellents: from discovery and
481 development to evidence-based validation. Malar J 2012;11:164.

482 13. World Health Organization. WHO pesticide evaluation scheme [Internet]. World
483 Health Organization; 2013. Available from:
484 http://www.who.int/iris/handle/10665/78142

485 14. WHO | Vector Control Advisory Group. 2020 [cited 2020 Nov 26];Available from:
486 https://www.who.int/vector-control/vcag/en

487 15. Hill N, Zhou H, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized,
488 controlled trial of the efficacy of 0.03% transfluthrin coils alone and in
489 combination with long-lasting insecticidal nets on the incidence of Plasmodium
490 falciparum and Plasmodium vivax malaria in Western Yunnan Province, China
491 [Internet]. Malaria Journal. 2014;13(1):208. Available from:
492 http://dx.doi.org/10.1186/1475-2875-13-208

493 16. Syafruddin D, Asih PBS, Rozi IE, et al. Efficacy of a Spatial Repellent for Control
494 of Malaria in Indonesia: A Cluster-Randomized Controlled Trial. Am J Trop Med
495 Hyg [Internet] 2020;Available from: http://dx.doi.org/10.4269/ajtmh.19-0554

496 17. Vazquez-Prokopec GM, Bisanzio D, Stoddard ST, et al. Using GPS technology
497 to quantify human mobility, dynamic contacts and infectious disease dynamics in
498 a resource-poor urban environment. PLoS One 2013;8(4):e58802.

499 18. Vazquez-Prokopec GM, Stoddard ST, Paz-Soldan V, et al. Usefulness of
500 commercially available GPS data-loggers for tracking human movement and
501 exposure to dengue virus. Int J Health Geogr 2009;8:68.

502 19. Gunning CE, Okamoto K, Astete H, et al. Efficacy of Aedes aegypti control by
503 indoor Ultra Low Volume (ULV) insecticide spraying in Iquitos, Peru. PLoS Negl
504 Trop Dis 2018;12(4):e0006378.

505 20. R Core Team. R: A language and environment for statistical computing. R
506 Foundation for Statistical Computing [Internet]. Vienna, Austria; 2019. Available
507 from: http://www.R-project.org/.

508 21. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models
509 using lme4 [Internet]. arXiv [stat.CO]. 2014;Available from:
510 http://arxiv.org/abs/1406.5823

511 22. Therneau TM. A Package for Survival Analysis in S. version 2.38 [Internet]. 2015
512 [cited 2021 Jan 19];Available from: http://cran.r-project.org/package=survival

513 23. Palomino-Salcedo M. [Estado de susceptibilidad de la población natural de
514 Aedes aegypti a los insecticidas en Punchana-Iquitos, Región Loreto (Novimbre
515 2014). Instituto Nacional de Salud, Peru; 2014.

516 24. Norris E, Coats J. Current and future repellent technologies: The potential of
517 spatial repellents and their place in mosquito-borne disease control. Int J Environ
518 Res Public Health 2017;14(2):124.

519 25. Syafruddin D, Bangs MJ, Sidik D, et al. Impact of a spatial repellent on malaria
520 incidence in two villages in Sumba, Indonesia. Am J Trop Med Hyg
521 2014;91(6):1079–87.

522 26. Liverani M, Charlwood JD, Lawford H, Yeung S. Field assessment of a novel
523 spatial repellent for malaria control: a feasibility and acceptability study in
524 Mondulkiri, Cambodia. Malar J 2017;16(1):412.

525 27. Masalu JP, Finda M, Okumu FO, et al. Efficacy and user acceptability of
526 transfluthrin-treated sisal and hessian decorations for protecting against
527 mosquito bites in outdoor bars. Parasit Vectors 2017;10(1):197.

528 28. Paz-Soldan VA, Plasai V, Morrison AC, et al. Initial assessment of the
529 acceptability of a Push-Pull Aedes aegypti control strategy in Iquitos, Peru and
530 Kanchanaburi, Thailand. Am J Trop Med Hyg 2011;84(2):208–17.

531 29. Jumbam DT, Stevenson JC, Matoba J, et al. Knowledge, attitudes and practices
532 assessment of malaria interventions in rural Zambia. BMC Public Health
533 2020;20(1):216.

534 30. World Health Organization. The evaluation process for vector control products
535 [Internet]. World Health Organization; 2017 [cited 2020 Dec 2]. Available from:
536 https://apps.who.int/iris/handle/10665/255644

537 31. [Cited 2020 Dec 2];Available from:
538 https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-
539 per.pdf

540 32. Anders KL, Cutcher Z, Kleinschmidt I, et al. Cluster-Randomized Test-Negative
541 Design Trials: A Novel and Efficient Method to Assess the Efficacy of
542 Community-Level Dengue Interventions. Am J Epidemiol 2018;187(9):2021–8.

Figure 1. Location of 26 study clusters in Iquitos and Punchana Districts, Loreto Department, Iquitos, Peru. Each cluster consisted of ca. 140 households with an average distance of 300m between clusters.



548 **Figure 2.** Study timeline. Top panel: Human blood-sampling, disease surveillance,
549 and entomological monitoring in relation to deployment of the spatial repellent
550 intervention. Bottom panel: Intervention roll-out between August-December 2016 by
551 cluster (horizontal numbers correspond to cluster numbers shown in Figure 1).



552

553

554

Figure 3. Allocation and follow-up of the longitudinal cohort population during three collection periods (Baseline [B], First [F] and Second/Final [S]). The majority (62%) of participants provided blood samples at each collection period, whereas some only during year 1 (B-F) or year 2 (F-S). Participants with a single sample were lost to follow-up and four individuals who moved or had two houses located in the spatial repellent and placebo clusters are shown as removed at the baseline period for clarity.



563 **Table 1.** Summary of baseline characteristics, for qualifying participants of the intent-
564 to-treat (ITT) longitudinal cohort population in spatial repellent (SR) and placebo arm.
565 Qualifying participants were defined as individuals in a participating house who were
566 seronegative or had a monotypic DENV antibody response when they entered the
567 trial.

Individual-Level		
Variable	SR (n=898)	Placebo (n=952)
Age in years (mean±sd) (min, max)	10.88±4.62 (2,47)	10.19±4.39 (2,22)
Sex (% male)	51.6%	55.0%
Duration in years between samples (mean±sd) (min, max)	1.15±0.42 (0.02,2.29)	1.16±0.43 (0.01,2.35)
No. qualifying participant observations	1,090	1,237
No. of arbovirus seroconversions	196	294
Cluster-Level		
Variable	SR (n=13)	Placebo (n=13)
Cluster population (mean±sd) (min, max)	58.2±30.4 (21,124)	73.5±35.3 (12,132)
Baseline susceptibility (mean±sd) (min, max)	81.0%±12.8% (54.7%,98.1%)	84.9%±6.3% (73.3%,92.5%)

568

569 **Table 2**. Protective efficacy (PE) of the spatial repellent (SR) intervention against

570 *Aedes*-borne virus (ABV) infection.

SR vs placebo comparison	95% one-sided CI	PE (%) (95% one-sided CI)	One-sided p-value
Intent-to-treat (ITT) analysis (reduction in ABV seroconversion rates)			
Survival analysis Hazard ratio	0.694 (−∞,0.955)	34.1 (6.9, ∞)	0.0236

571